Macular degeneration trials in Switzerland

In Switzerland 11 Also abroad 220

11 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Where
Basel, Bern, Olten
Age
60 years and over
People
240 worldwide
Run by
ADARx Pharmaceuticals, Inc.
See details and how to joinNCT06990269 · EU 2025-521779-30-00
Phase 3Taking people
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Where
Bern, Olten, Sankt Gallen
Age
50 years and over
People
250 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06847542 · EU 2024-516924-32-00
Phase 2/3Taking people
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Where
Bern
Age
60 years and over
People
274 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06635148 · EU 2022-500747-21-00
Phase 3Taking people
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Where
Basel, Bern, Binningen, Lausanne, Zurich
Age
50 years and over
People
1,000 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT03683251 · EU 2023-507131-38-00
Phase 2/3Taking people
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Where
Basel, Bern, Binnigen, Lausanne, Zurich
Age
50 years and over
People
960 worldwide
Run by
EyeBiotech Ltd.
See details and how to joinNCT07440225
Phase 2Not yet taking people in Switzerland
A Study in Adults With Geographic Atrophy
Where
Bellinzona, Bern, Binningen, Lausanne, Zurich
Age
60 years and over
People
300 worldwide
Run by
Sitala Bio LTD
See details and how to joinNCT07606365 · EU 2026-525738-40-00
Phase 3Taking people
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
Where
Bern, Lausanne
Age
50 years to 120 years
People
210 worldwide
Run by
King's College Hospital NHS Trust
See details and how to joinNCT04663750 · EU 2023-504751-28-00
Phase 2Taking people
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
Where
Bern, Binningen, Lausanne, Zurich
Age
55 years and over
People
324 worldwide
Run by
ONL Therapeutics
See details and how to joinNCT06659445 · EU 2024-513174-22-00
No phaseTaking people
EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).
Where
Bern
Age
50 years and over
People
50
Run by
Insel Gruppe AG, University Hospital Bern
See details and how to joinNCT07434713
No phaseTaking people
Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression
Where
Binningen, Zurich
Age
55 years to 99 years
People
200 worldwide
Run by
Medical University of Vienna
See details and how to joinNCT06351657
No phaseTaking people
Personalised Monitoring of Early and Intermediate Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression
Where
Binningen, Zurich
Age
55 years to 99 years
People
500 worldwide
Run by
Medical University of Vienna
See details and how to joinNCT06351670